Dean&Francis
ISSN 2959-409X

CRISPR Applications in Metabolic Disease Treatment: A Case of Hyperuricemia

Junlin Zhou[1,*]

[1]School of Life Sciences, Zhejiang Chinese Medical University, Zhejiang, China
*Corresponding author: zhoujunlin442@gmail.com

Abstract:

The condition of hyperuricemia, which refers to elevated uric acid levels in blood, has become a widespread metabolic disorder that leads to gout development and increases the risk of various metabolic and cardiovascular and renal diseases. The number of people with this condition continues to rise across the globe. The formation of monosodium urate crystals in joints leads to gout, which causes severe joint inflammation that severely impacts the life quality of patients. The current treatment options for hyperuricemia include allopurinol and uricosurics which either reduce uric acid production or enhance its elimination but patients need to continue their medication forever. The treatment fails to resolve the underlying condition. The rapid development of CRISPR/Cas9 gene editing technology during the last few years created a new method to address the fundamental causes of metabolic diseases including hyperuricemia. The paper examines the potential of CRISPR technology to treat metabolic diseases through the example of hyperuricemia treatment. The research investigates multiple approaches which work to achieve uric acid homeostasis and optimize urate transport and regulating uric acid production related metabolic pathways. The research examines current gene editing systems and new delivery techniques which enable successful in vivo applications. The paper presents current developments while identifying remaining obstacles that prevent laboratory breakthroughs from reaching clinical practice and suggests future directions for CRISPR hyperuricemia treatment.

Keywords: CRISPR/Cas9; hyperuricemia; metabolic disease; gene editing therapy; inflammation.

1. Introduction

Hyperuricemia (HUA) is a metabolic disorder marked by persistently elevated serum uric acid levels. With the surge in metabolic syndrome and shifting habits, the condition's prevalence has climbed

ISSN 2959-409X

sharply over recent decades. Epidemiological studies show that more than 20% of adult men in China are affected, and the trend keeps rising among cohorts, with some regions reporting rates that exceed 25%. The first sign of gout appears as hyperuricemia, which also connects to obesity and insulin resistance and type-2 diabetes and non-alcoholic fatty liver disease and chronic kidney disease and multiple other health conditions[1]. The most common expression of hyperuricemia leads to gout through monosodium urate (MSU) crystal accumulation in joints and soft tissues which causes painful inflammatory episodes. The condition of chronic hyperuricemia leads to kidney problems and tubular interstitial fibrosis and systemic metabolic disturbances which are not well recognized as part of metabolic syndrome pathology.

The formation of elevated uric acid leads to gout when MSU crystals accumulate in joints and soft tissues to create sudden and severe inflammatory attacks that cause extreme pain. The prolonged presence of hyperuricemia leads to functional impairment and promotes interstitial fibrosis and disrupts overall metabolic equilibrium, which represents an underdiagnosed aspect of metabolic syndrome. Medical practitioners choose between two types of drugs to treat gout: allopurinol or febuxostat, which stop uric acid production, and benzbromarone, which helps the kidneys remove uric acid. These agents require extended treatment periods but they cause liver and kidney damage and the condition returns after patients stop taking them. When hyperuricemia originates from hereditary causes, the standard pharmacologic arsenal simply doesn't mend the underlying defect. As precision medicine and gene therapy race forward, gene-editing methods are emerging as an alternative for metabolic disorders. In this arena, the CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)/Cas system stands out for its simplicity, impressive efficiency, and broad applicability[2].

The CRISPR/Cas9 system operates as a bacterial adaptive immune system which enables RNA-based DNA cutting at particular positions. The CRISPR system offers superior programmability and scalability compared to previous genome-editing tools including zinc-finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs) which enable efficient modification of metabolic genes. Scientists use the CRISPR/Cas9 system to create animal models of hyperuricemia and study uric acid metabolism and transport and inflammatory responses. The CRISPR technology allows scientists to create mice with UOX gene deletions which leading to hyperuricemia,renal impairment, and metabolic abnormalities that match human gout symptoms. Scientists can use base editors (BE) and prime editors to make exact mutation changes and small insertion edits without generating double-strand breaks, which results in better control and safety during editing operations. The therapeutic potential of CRISPR technology extends beyond enzyme modification for treating hyperuricemia and gout. The modification of Urate Transporter 1 (URAT1) and Glucose Transporter 9 (GLUT9) and ATP-Binding Cassette Subfamily G Member 2 (ABCG2) transporters through CRISPR editing could result in enhanced uric acid removal from the body. Scientists can prevent gout attacks by using targeted gene editing to disable NOD-Like Receptor Family Pyrin Domain Containing 3 (NLRP3) and Interleukin-1 Beta (IL-1β) genes. The discovery presents a fresh method to treat metabolic diseases through multiple precise interventions which establishes CRISPR as an advanced therapeutic system.

All told, the worldwide upswing in hyperuricemia makes it clear that we urgently need therapies that go after the disease's underpinnings. The CRISPR/Cas toolbox, with its editing promises a way to tip the metabolic scales back toward balance. In this review we zero in on hyperuricemia and gout as cases, laying out step by step the strides in regulating uric-acid metabolism, transport and the inflammatory cascade—while also weighing the practical hurdles and the translational outlook for CRISPR-based gene therapy, in metabolic disorders.

2. Molecular Mechanism of Hyperuricemia

Hyperuricemia arises when the body either cranks out uric acid or fails to flush it out efficiently. A significant aspect of the situation is a hitch. Humans lost a functional uricase as our UOX gene became inactive during primate evolution, which means we are unable to convert uric acid into the much more soluble allantoin[3]. This loss leads to the accumulation of uric acid as the end-product of purine metabolism. At the same time, genetic variations in renal and intestinal urate transporters can be seen in Fig. 1, which can reduce the efficiency of urate excretion, exacerbating elevations in serum uric acid[4]. When urate levels exceed the saturation threshold, needle-shaped MSU crystals may deposit in joints and other tissues. These crystals are recognized by the innate immune system and trigger the activation of the NOD-Like Receptor Family Pyrin Domain Containing 3 inflammasome, leading to the release of IL-1β and causing the acute inflammation characteristic of gout flares. Chronic hyperuricemia can also result in tophi formation and long-term joint damage, as well as renal impairment due to urate crystal deposition in the kidneys. In summary, hyperuricemia and gout arise from a combination of metabolic, transport, and immune

dysregulation, presenting multiple potential targets for therapeutic gene intervention.



Fig. 1 Uric acid transport and regulation in the kidney and intestine[1]

3. CRISPR Interventions in Uric Acid Metabolism

CRISPR applications lie in the prospect of reprogramming the enzymes that churn out uric acid, essentially pulling the plug on urate production at its very source. For instance, researchers have harnessed CRISPR/Cas9 to delete the Uox gene in mice, creating a hyperuricemia model in which the engineered rodents display a surge in blood uric acid accompanied by kidney injury and a cascade of cardiovascular-metabolic disturbances that closely mirror the complications seen in humans[5]. This outcome underscores the role of UOX in preserving urate homeostasis. Conversely, restoring or introducing uricase activity via CRISPR has shown therapeutic potential. In an experiment, a team coaxed a UOX pseudogene awake in primate cells by way of CRISPR, and the resulting surge of uricase activity drove down intracellular urate concentrations and throttled lipid deposition under a high-fructose assault[6]. In an approach, Balico and collaborators slipped an ancestral uricase construct into a genomic safe-zone of human liver cells, demonstrating that persistent uricase production can mute acute uric-acid spikes and reshape cellular metabolic profiles[7]. These proof-of-concept studies suggest that gene editing strategies to reintroduce or enhance uricase function could correct the fundamental metabolic defect in hyperuricemia.

For example, CRISPR could be employed to patch up defects in purine-metabolism enzymes, think deficiency that causes Lesch-Nyhan syndrome, or to knock out xanthine dehydrogenase (XDH) so as to trim down uric-acid synthesis. Such gene-editing strategies would directly blunt the production of acid. The complete removal of urate production creates safety risks because urate serves as a body antioxidant while helping to regulate metabolic processes. The process of gene editing needs precise adjustment to prevent negative consequences from low uric acid levels because urate serves protective functions in

ISSN 2959-409X

the brain and hypouricemia creates additional health problems. The therapeutic method CRISPR demonstrates two possible treatments for hyperuricemia by either correcting dysfunctional urate-metabolizing enzymes or controlling urate production levels.

4. CRISPR Interventions in Urate Transport

Research into genetic variations has identified multiple variants in urate transporter genes which determine uric acid elimination and show strong links to gout development[4]. The Urate Transporter 1 (SLC22A12) gene contains a loss-of-function mutation which results in hypouricemia and decreased gout risk, but the Q141K polymorphism in ATP-Binding Cassette Subfamily G Member 2 transporter reduces urate efflux and increases gout risk[8]. The research findings indicate that gene editing techniques can create loss-of-function and correct loss of function mutations or enhancement functional activity. The CRISPR gene editing tool enables scientists to modify urate transporter function through specific gene modifications. Scientists can use CRISPR to modify urate transporter function by reducing Urate Transporter 1 activity in cells, which would decrease urate reabsorption and increase uric acid excretion into urine and decrease blood urate blood levels. Scientists can use CRISPR to modify the ATP-binding cassette subfamily G member 2 gene in gut and kidney cells to enhance their transport abilities, which would increase secretion. The process leads to better urate removal from the body.

Multiple research studies have proven that this approach works effectively. The CRISPR system was used in cell culture experiments to introduce a Urate Transporter 1 mutation which validated that reducing this transporter's function would produce the expected changes in uric acid levels. The research findings indicate a method to achieve uricosuric drug effects through gene editing of urate transport and secretion regulators. The process requires careful attention because excessive urate level reduction through gene editing may result in hypouricemia, which increases the chances of developing uric acid stones in the kidneys. The management of these risks requires precise control of gene knockout levels and possibly using editing systems that can be turned on and off. The future development of CRISPR-based somatic gene therapy will enable doctors to perform exact modifications of patient-specific transporter gene mutations which will lead to personalized uric acid management. The method uses genetic information from each patient to create customized gene editing treatments which optimize urate homeostasis for their specific needs.

5. CRISPR Interventions in Inflammation Regulation

Acute gout attacks function as an immune system reaction which occurs when urate crystals trigger the NOD-Like Receptor Family Pyrin Domain Containing 3 inflammasome to release IL-1β and multiple other inflammatory cytokines. The treatment of gout flare symptoms includes IL-1β-blocking biologics which are standard anti-inflammatory medications. The treatment approach should not alter the core disease mechanisms or stop the occurrence of attacks.

The research now demonstrates that this method works as a proof-of-concept. Xu et al. used CRISPR/Cas9 to remove the NOD-Like Receptor Family Pyrin Domain Containing 3 gene from macrophages, which resulted in complete inflammasome deactivation when exposed to different triggers[9]. The researchers embedded NLRP3-targeted CRISPR cargo into positively charged nanoliposomes for delivery to mice. The researchers used this method to deliver the treatment to mice. The treatment method successfully reduced MSU crystal-induced inflammation in mice to zero, which resulted in complete prevention of acute gout attacks in the animal model[10]. The CRISPR-NLRP3 approach demonstrated its ability to reduce inflammation in mice that consumed high-fat diets through decreased adipose tissue inflammation and enhanced insulin sensitivity. The research indicates that blocking specific pathways can produce metabolic advantages which reach beyond the treatment of gout. The gout inflammatory process can be stopped at its beginning point through CRISPR gene editing of innate immune system genes, which would prevent the severe pain and joint destruction that occurs during gout attacks. The treatment method enables permanent protection against gout attacks through cell modification which reduces their response to MSU crystals and their chemical messenger production.

6. Gene Editing Tools and Delivery Systems: Advances and Challenges

The research on metabolic diseases continues to use CRISPR/Cas9 nuclease as its primary gene-editing tool because this enzyme functions as a scissor to create double-strand breaks which facilitate the delivery of specific DNA segments. Base editors function as engineered fusion proteins which enable precise DNA nucleotide substitutions at specific target locations without damaging the DNA backbone[11]. The new prime editing technol-

ogy has joined the scientific arsenal because it enables DNA fragment insertion and replacement operations which extend the reach of base editing beyond its current limitations. Scientists have developed multiple Cas9 variants and new editing enzymes to enhance gene editing precision and minimize unwanted target interactions. The developed editing methods enable researchers to select the most suitable approach for their specific mutation types. The base-editing (ABE) technology serves as a prime example because it successfully treated a non-human primate model with a disease-causing mutation and researchers are now testing its safety for cholesterol reduction in human trials[11]. The development of advanced editing tools shows promise for treating genetic mutations which were previously unmanageable.

The current advancements demonstrate how future gene editing systems will succeed in modifying mutations which were difficult to edit before. The main obstacle for gene editing treatments involves delivering CRISPR machinery to specific tissues and cells. The field continues to encounter delivery challenges. Viral vectors serve as a solution to deliver CRISPR components through adeno-associated virus (AAV) vectors which successfully transport genes to liver cells and other organs for efficient targeted gene insertion in animal models[12]. AAV-CRISPR technology enabled scientists to modify liver genes in hemophilic mice through successful genome integration and functional restoration[12]. The development of non-viral delivery systems has shown significant progress since the last update. The combination of Cas9 mRNA with guide RNA inside lipid nanoparticles (LNPs) enables liver-specific gene editing after intravenous injection. The first human CRISPR therapy trial used LNP delivery to transport CRISPR-Cas9 for transthyretin amyloidosis treatment which resulted in protein Transthyretin cuts throughout the patient population[13]. Scientists who work with hematopoietic stem cells use advanced delivery techniques including electroporation and nanoparticle-based transfection to introduce CRISPR components into patient-derived cells. The body receives edited cells after scientists verify the editing process through a procedure shown in Fig. 2.

The different delivery methods of genetic material require different sets of trade-offs during their use. Viral vectors achieve high efficiency when they transport genetic material. The delivery system faces two major restrictions because it activates immune system surveillance and has restricted capacity for cargo transport. Lipid nanoparticles function without needing additional components. The production process for these nanoparticles scales well but scientists need to optimize their delivery methods for tissue targeting and they can trigger immune responses and move away from their intended targets. The main difficulty exists in finding the right balance between delivery strength and safety measures. The development of vector engineering techniques which include promoter design for tissue specificity and surface ligand attachment for cell targeting has started to create effective targeted therapies. The development of delivery technologies brings CRISPR payload delivery inside human bodies closer to reality, which enables precise gene editing for metabolic disease treatment.



Fig. 2 Ex vivo and in vivo CRISPR-based therapeutic strategies[13]

7. Current Progress and Remaining Challenges

Medical researchers continue to advance gene editing treatments for metabolic disorders from laboratory testing to human clinical use. The research using cell and animal models of hyperuricemia demonstrates that CRISPR technology successfully repairs metabolic disorders at

ISSN 2959-409X

their fundamental level. Multiple new treatments for inherited metabolic diseases now participate in clinical trials which take place across different countries. Researchers have achieved successful results with an in-vivo CRISPR therapy that treats transthyretin amyloidosis by reducing the disease-causing protein according to trial data[13]. Scientists can now use base-editing and prime-editing technologies to fix both simple point mutations and complex genetic defects which were previously considered unfixable. The biotechnology company Beam Therapeutics has started clinical trials with base-editing therapy for metabolic disorders which show promising results for maintaining permanent mutation fixes[14]. The scientific community now witnesses the fulfillment of gene editing technology through these groundbreaking discoveries. The genome receives unintended CRISPR edits which produce mutations that could lead to growth abnormalities or disable essential gene functions. Researchers need to establish safety measures through precise gRNA design tools and preclinical off-target profiling to minimize unwanted genetic changes and defend patients from adverse effects. The development of CRISPR-based therapies faces multiple obstacles which need to be overcome before they can become medical treatments. The main obstacles for CRISPR-based therapies to become clinical treatments stem from two main issues. The Cas9 protein within the CRISPR toolbox becomes detectable by the patient's immune system, which triggers an immune response. The risk of this occurrence increases when multiple or systemic doses are administered. The immune system response against the treatment could reduce its effectiveness. The need to reduce immunogenicity becomes critical for both repeated and extended use of the treatment. The system can be delivered through specific agents while using Cas variants from bacterial sources that humans encounter rarely. The combination of genetic factors and environmental elements makes gout and other diseases complicated to treat. A single gene modification will not provide a permanent solution for managing the condition. The long-term effectiveness and manageability of a single genetic modification needs assessment through studies conducted on complete organisms. The evaluation process must determine if single or multiple gene targets produce enduring therapeutic effects during multifactorial disease treatment while monitoring potential biological responses that could reduce treatment effectiveness. The development of metabolic disorder treatments has shown rapid progress but researchers need to complete extensive safety and effectiveness testing before these treatments can enter clinical use. The development of genome editing precision requires delivery systems and preclinical testing protocols which must be followed by clinical trials that assess both treatment effectiveness and patient safety over time.

8. Conclusion

The clinical application of CRISPR for hyperuricemia treatment needs researchers to solve multiple essential problems.

The development of a practical hyperuricemia treatment depends on scientists creating gene-editing methods which target separate components of the disease mechanism. A complete treatment program for hyperuricemia could involve three main steps: liver directed gene editing for enzyme restoration and kidney cell modification to enhance urate elimination through transporter gene adjustments and immune cell pro-inflammatory mediator gene suppression for gout flare prevention. The combination of three distinct approaches to reduce urate levels and enhance acid elimination and minimize inflammation would create an effective treatment plan. The research will focus on developing a treatment method which combines these steps through a staggered approach. The research needs to determine both the best method for delivering the treatment and when to administer it. A treatment approach needs to be developed for patients with inherited hyperuricemia and genetic predisposition to gout. The treatment of inherited hyperuricemia requires liver-directed gene correction through in vivo delivery during life to prevent long-term complications from chronic hyperuricemia. The treatment of refractory gout in adults might involve ex vivo cell therapy which starts with hematopoietic stem cell extraction followed by CRISPR editing for immune system regulation and then cell reinfusion into the body. The autologous cell therapy approach would create a gout-resistant system which eliminates the requirement for medication. The development of clinical protocols depends on researchers determining the optimal treatment period and choosing between in vivo gene therapy and ex vivo cell therapy approaches.

Personalized medicine lives up to its name by establishing precise interventions. The future will reveal the exact genetic pattern which determines individual disease susceptibility through DNA sequencing technology. The development of personalized treatments would enable scientists to create individualized guide RNAs and editing methods which target each person's unique set of genetic variants. The customized treatment method enables doctors to perform unique gene modifications for patients based on their Urate Transporter 1 allele and inflammasome-related disease causes. The advancement of CRISPR tools and genetic diagnostics creates a path toward making gene-editing treatments for metabolic disorders possible.

The existing points about gene-editing therapies require

additional discussion about the need for improved regulatory and ethical standards. The development and application of CRISPR-based treatments requires strict oversight to achieve controlled and fair results. The development of gene-editing therapies requires specific guidelines for clinical trial operations and patient monitoring programs and proper management of ethical concerns about germline editing for hyperuricemia treatment since all proposed methods target somatic cells. The implementation of these innovative medical treatments faces difficulties regarding their availability and cost affordability to benefit all people instead of restricted access to wealthy patients. Patients will benefit from permanent disease treatment through single gene editing procedures which will create enduring molecular solutions for better life quality. The initial success of gene editing treatments for metabolic diseases has created valuable information and operational expertise which scientists predict will eventually help treat hyperuricemia and gout. The development of CRISPR-based interventions as a single treatment for these disorders will become possible after successful validation in animal models and completion of clinical testing stages. A breakthrough in this field would create a new medical standard because current treatment methods focus on maintaining controlled urate levels..

References

[1] Du L, Zong Y, Li H, et al. Hyperuricemia and its related diseases: mechanisms and advances in therapy. Signal Transduction and Targeted Therapy, 2024, 9: 212.

[2] Li T, Yang Y, Qi H, et al. CRISPR/Cas9 therapeutics: progress and prospects. Signal Transduction and Targeted Therapy, 2023, 8: 36.

[3] Dalbeth N, Choi H K, Joosten L A B, et al. Gout. Nature Reviews Disease Primers, 2019, 5: 69.

[4] Sun HL, Wu YW, Bian HG, et al. Function of uric acid transporters and their inhibitors in hyperuricaemia. Front Pharmacol. 2021, 12:667753.

[5] Zeng L, Shali S, Gao Y, et al. CRISPR/Cas9-mediated deletion of the Uox gene generates a mouse model of hyperuricemia with multiple complications. Journal of Cardiovascular Translational Research, 2024, 17(6): 1455-1465.

[6] Balico L D, Gaucher E A. CRISPR-Cas9-mediated reactivation of the uricase pseudogene in human cells prevents acute hyperuricemia. Molecular Therapy – Nucleic Acids, 2021, 25: 578-584.

[7] Balico L D, Gaucher E A. Genomic insertion of ancestral uricase into human liver cells to determine metabolic consequences of pseudogenization. Scientific Reports, 2025, 15: 26093.

[8] Woodward O M, Köttgen A, Coresh J, et al. Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. Proceedings of the National Academy of Sciences of the USA, 2009, 106(25): 10338-10342.

[9] Xu C, Lu Z, Luo Y, et al. Targeting of NLRP3 inflammasome with gene editing for the amelioration of inflammatory diseases. Nature Communications, 2018, 9: 4092.

[10] Liu Y R, Wang J Q, Li J. Role of NLRP3 in the pathogenesis and treatment of gout arthritis. Frontiers in Immunology, 2023, 14: 1137822.

[11] Kingwell K. Base editors hit the clinic. Nature Reviews Drug Discovery, 2022, 21: 545-547.

[12] He X, Zhang Z, Xue J, et al. Low-dose AAV-CRISPR-mediated liver-specific knock-in restored hemostasis in neonatal hemophilia B mice with a subtle antibody response. Nature Communications, 2022, 13: 7275.

[13] Gillmore J D, Gane E, Taubel J, et al. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. New England Journal of Medicine, 2021, 385(6): 493-502.

[14] Li T, Yang Y, Qi H, et al. CRISPR/Cas9 therapeutics: progress and prospects. Signal Transduction and Targeted Therapy, 2023, 8: 36.